Danaher shares fell more than 4% in premarket trading on October 21, 2026, after third-quarter revenue narrowly missed analyst expectations. The life sciences and diagnostics company nevertheless beat adjusted earnings estimates and raised its full-year profit guidance.
Key Takeaways
- Quarterly revenue reached $6.55 billion, about $10 million below analyst expectations.
- Adjusted earnings of $2.11 per share beat estimates by $0.19.
- Danaher raised its 2026 adjusted EPS forecast to $8.57–$8.62 from $8.45–$8.60.
Table of Contents
- Danaher shares retreat as revenue falls short
- Biotechnology trails expectations as other segments outperform
- Higher annual profit guidance accompanies respiratory headwind
- Conclusion
Danaher shares retreat as revenue falls short
The quarterly results presented a split picture against market expectations: sales fell slightly short, while adjusted profit exceeded forecasts. The premarket decline came despite growth in both revenue and earnings from a year earlier.
Danaher’s third-quarter results announcement recorded sales of $6.554 billion for the three months ended September 25, 2026. Adjusted diluted earnings per share, a non-GAAP measure, increased to $2.11 from $1.89 a year earlier.
On a GAAP basis, diluted earnings from continuing operations rose to $1.71 per share from $1.27. That measure is distinct from the adjusted figure used in the analyst comparison.
| Item | Details |
|---|---|
| Diagnostics revenue | Approximately $2.88 billion; above analyst forecasts |
| Life sciences revenue | Approximately $1.87 billion; above analyst forecasts |
| Biotechnology revenue | $1.80 billion versus $1.87 billion expected |
Biotechnology trails expectations as other segments outperform
Diagnostics and life sciences revenue exceeded analyst forecasts, at approximately $2.88 billion and $1.87 billion, respectively. Biotechnology revenue of $1.80 billion fell below the expected $1.87 billion, leaving the segment about $70 million short of expectations.
Underlying growth also varied by measure. Danaher reported non-GAAP core revenue growth of 3.0%, compared with 5.5% when respiratory revenue was excluded. The difference shows how respiratory sales weighed on the broader core growth rate.
Chief Executive Officer Julie Sawyer Montgomery said the company saw improving trends across its end markets. Operating cash flow totaled $1.9 billion, while non-GAAP free cash flow reached $1.6 billion.
Higher annual profit guidance accompanies respiratory headwind
Danaher lifted its full-year adjusted diluted EPS guidance to $8.57–$8.62, above the cited analyst consensus of $8.51. The new range raises both the lower and upper ends of the previous $8.45–$8.60 forecast.
For the fourth quarter of 2026, management expects core revenue growth excluding respiratory revenue of 4.0%–5.0%. Respiratory revenue is expected to create an approximately 150-basis-point headwind, bringing overall core revenue growth to about 3.0%. These figures are management forecasts, not completed results.
Conclusion
The next reporting checkpoint is fourth-quarter performance against Danaher’s core revenue outlook and its higher annual adjusted EPS range. The immediate market reaction contrasted with stronger year-over-year earnings and management’s increased profit forecast.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
